<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098596</article-id><article-id pub-id-type="publisher-id">1593241</article-id><article-id pub-id-type="doi">10.3389/fcell.2025.1593241</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Biological disturbance of MiR-425 and its application prospects in cardiovascular diseases</article-title><alt-title alt-title-type="left-running-head">Zhou and Han</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fcell.2025.1593241" ext-link-type="uri">10.3389/fcell.2025.1593241</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Shan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1535017/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Han</surname><given-names>Bo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/715182/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Pediatric Cardiology</institution>, <institution>Shandong Provincial Hospital Affiliated to Shandong first Medical University</institution>, <addr-line>Jinan</addr-line>, <addr-line>Shandong</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>The Laboratory of Medical Science and Technology Innovation Center (Institute of Biomedical Engineering and Interdisciplinary Studies)</institution>, <institution>Shandong First Medical University</institution>, <addr-line>jinan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/1002152/overview" ext-link-type="uri">Giovanni Nassa</ext-link>, University of Salerno, Italy</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/1751127/overview" ext-link-type="uri">Viola Melone</ext-link>, University of Salerno, Italy</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/2537488/overview" ext-link-type="uri">Domenico Palumbo</ext-link>, University of Salerno, Italy</p></fn><corresp id="c001">*Correspondence: Bo Han, <email>hanbo35@163.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>1593241</elocation-id><history><date date-type="received"><day>13</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhou and Han.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhou and Han</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>MiR-425 is a biological molecule that has potential applications in cardiovascular diseases. It can regulate biological functions by combining with LncRNAs, binding with proteins, and changing the differentiation of immune cells. MiR-425 also has a role as a biomarker of disease. In cardiovascular diseases, it has clinical significance in reducing inflammation and heart repair, inducing angiogenesis, improving the prediction of atherosclerosis, reducing cardiac fibrosis, and regulating atrial natriuretic peptide to affect cardiovascular function. Target gene prediction and KEGG enrichment analysis are also mentioned.</p></abstract><kwd-group><kwd>MiR-425</kwd><kwd>biological disturbance</kwd><kwd>cardiovascular diseases</kwd><kwd>application</kwd><kwd>gene prediction</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">8187020860</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Natural Science Foundation of Shandong Province
</institution><institution-id institution-id-type="doi">10.13039/501100007129</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">ZR2023MH052</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was financially supported by the National Natural Science Foundation of China (No. 8187020860), the Natural Science Foundation of Shandong Province (No. ZR2023MH052), and the Science and Technology Development Program of Jinan (No. 202134015).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Epigenomics and Epigenetics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>MicroRNAs (miRNAs) are non-coding RNA molecules containing 21 to 23 nucleotides. These molecular entities are ubiquitously distributed across botanical, zoological, and select viral organisms. Such regulatory molecules participate critically in RNA suppression mechanisms and modulate post-transcriptional genetic expression dynamics. These abbreviated genomic modulators orchestrate precise nucleotide complementarity with specific messenger ribonucleic acid transcript fragments. The regulatory mechanisms encompass multiple strategic interventions: fragmenting targeted RNA strands into discrete molecular components, inducing transcript instability through poly (A) tail truncation, or marginally suppressing protein translation processes. Structurally, these genetic regulatory elements demonstrate remarkable similarities to small interfering ribonucleic acid molecules within RNA interference cascades. Notably, distinctive biogenesis pathways differentiate these molecular actors: the compact regulatory sequences emerge from intricate RNA transcript regions capable of forming condensed hairpin configurations, whereas their counterpart interference RNAs originate from extended double-stranded RNA molecular domains (<xref rid="B19" ref-type="bibr">Gan et al., 2022</xref>). Genomic computational analyses propose that the <italic>Homo sapiens</italic> genetic landscape potentially harbors approximately 1,900 to 2,300 compact regulatory ribonucleic acid sequences. Nevertheless, rigorous scholarly curation reveals a more conservative estimate, with merely 500 validated genetic elements meeting stringent molecular classification criteria within the authoritative microRNA gene repository (MirGeneDB). MiRNAs are released into body fluids including blood (<xref rid="B17" ref-type="bibr">Fan et al., 2025</xref>), urine (<xref rid="B65" ref-type="bibr">Wang et al., 2025</xref>), sweat (<xref rid="B31" ref-type="bibr">Karvinen et al., 2020</xref>), Human Breast Milk (<xref rid="B75" ref-type="bibr">Yi and Kim, 2021</xref>), Saliva (<xref rid="B63" ref-type="bibr">Urbizu et al., 2023</xref>), Tear (<xref rid="B1" ref-type="bibr">Altman et al., 2023</xref>) and cerebrospinal fluid (<xref rid="B48" ref-type="bibr">Noh et al., 2025</xref>) and have the potential to be available as biomarkers in a number of diseases.</p><p>Computational genomic investigations suggest that these compact regulatory ribonucleic acid molecules potentially modulate approximately 60% of genetic elements within human and mammalian systems (<xref rid="B26" ref-type="bibr">Hua et al., 2023</xref>). Phylogenetic analyses reveal substantial evolutionary conservation, indicating profound biological significance. Illustrative evidence emerges from comparative molecular studies, where identical genetic regulatory sequences have been systematically identified across divergent species, such as <italic>H. sapiens</italic> and murine cleft lip and palate developmental models, underscoring their critical functional roles (<xref rid="B76" ref-type="bibr">Yoshioka et al., 2021</xref>). The molecular landscape of these genetic modulators traces its initial scientific discovery to the nascent stages of the 1990s, though comprehensive recognition of their distinct regulatory mechanisms emerged during the early millennium. Subsequent comprehensive investigations unveiled intricate expression patterns across diverse cellular environments and tissue-specific contexts, demonstrating multifaceted contributions to organismal development and complex biological processes. Emerging translational research increasingly implicates aberrant expression patterns in pathological states, with innovative therapeutic strategies currently under rigorous investigational protocols (<xref rid="B12" ref-type="bibr">Diener et al., 2022</xref>).</p><p>The biogenesis of microRNAs occurs via two principal routes: the canonical and non-canonical pathways (<xref rid="B16" ref-type="bibr">Ergin and &#x000c7;etinkaya, 2022</xref>). Canonical Pathway: Genetic regulatory sequences undergo initial transcriptional processes mediated by RNA polymerase II, generating primary molecular precursors. These nascent transcriptional units subsequently experience nuclear processing via a sophisticated molecular machinery, encompassing the RNA-binding protein DiGeorge Syndrome Critical Region 8 (DGCR8) and the specialized ribonuclease III enzymatic component Drosha. Subsequent cytoplasmic translocation facilitates further molecular refinement through RNase III endonuclease intervention, culminating in mature duplex formation. Ultimately, selective strand incorporation into Argonaute (AGO) protein complexes establishes a regulatory silencing mechanism targeting specific messenger RNA transcripts. Alternative Pathways: Divergent biogenesis strategies predominantly include Drosha/DGCR8-independent and Dicer-independent molecular mechanisms. The intronic processing pathway enables direct precursor generation from messenger RNA interstices, circumventing traditional Drosha-mediated cleavage. Conversely, the Dicer-independent route involves specialized AGO2-mediated maturation of abbreviated endogenous short hairpin RNA transcripts, which are structurally incompatible with conventional Dicer processing protocols (<xref rid="B44" ref-type="bibr">Miao et al., 2024</xref>).</p><p>These two distinct isoforms emerge from opposite arms of the same pre-miRNA hairpin during the biogenesis process. The -5p variant originates from the 5&#x02032;arm, while the -3p variant derives from the 3&#x02032;arm. Despite sharing a common precursor, these isoforms possess different seed sequences that target distinct mRNA populations, thereby regulating separate gene networks and potentially exerting divergent or even opposing biological effects. In pathological contexts, miR-425-5p generally demonstrates oncogenic properties across multiple cancer types, promoting proliferation, invasion, and chemoresistance by targeting tumor suppressors like PTEN (<xref rid="B71" ref-type="bibr">Xiao et al., 2019</xref>) and CYLD (<xref rid="B72" ref-type="bibr">Yan et al., 2017</xref>). Contrastingly, miR-425-3p exhibits a more complex profile, functioning as a tumor suppressor in certain cancers (<xref rid="B79" ref-type="bibr">Zhang et al., 2022</xref>). In inflammatory and metabolic disorders, these isoforms can regulate different aspects of disease progression, with -5p often involved in cell survival pathways while -3p modulates inflammatory responses (<xref rid="B20" ref-type="bibr">Gao et al., 2024</xref>; <xref rid="B53" ref-type="bibr">Przybyci&#x00144;ski et al., 2025</xref>).</p><p>The tissue-specific expression patterns and context-dependent functions of these isoforms highlight the complexity of miRNA-mediated regulation. Their differential expression ratios may serve as valuable diagnostic and prognostic biomarkers, while their distinct regulatory networks offer potential therapeutic targets. Understanding the isoform-specific behaviors provides critical insights into disease mechanisms and may inform more precise therapeutic strategies for various pathological conditions.</p><p>Contemporary molecular investigations have unveiled an expansive repertoire of regulatory mechanisms beyond traditional gene expression suppression. Emerging research demonstrates that microRNAs exhibit sophisticated multifunctional capabilities. Preliminary transcriptional units potentially undergo translational processes, generating bioactive peptide configurations capable of executing diverse physiological roles through cytoplasmic interactions and ribosomal recognition (<xref rid="B22" ref-type="bibr">Goto and Suga, 2021</xref>). Furthermore, these molecular regulators establish intricate protein complexes with Argonaute-associated molecular machinery, transcending conventional degradative pathways. Their functional plasticity enables simultaneous engagement with alternative protein networks, facilitating nuanced regulatory cascades that extend beyond classical genetic modulation. Such sophisticated molecular strategies introduce unprecedented complexity and functional diversity to the regulatory landscape, challenging conventional understanding of genetic information processing. These sophisticated molecular mechanisms significantly expand our comprehension of genetic regulatory networks, revealing a multidimensional framework of post-transcriptional control that surpasses traditional conceptual boundaries. The emergent molecular paradigm underscores the remarkable adaptability and functional versatility of these compact genetic modulators.</p><p>In the development, progression, and regression of cardiovascular system miRNAs play a critical role (<xref rid="B84" ref-type="bibr">Zhou et al., 2018</xref>), such as myocardial infarction, hypertension, and atherosclerosis. The study of microRNAs in cardiovascular diseases has opened up new ways to develop diagnostic and treatment strategies (<xref rid="B45" ref-type="bibr">Michell and Vickers, 2016</xref>; <xref rid="B34" ref-type="bibr">Kontidou et al., 2023</xref>). In cardiovascular diseases, microRNAs have been discovered to play a role in controlling many different biological activities, such as maintaining mitochondrial function (<xref rid="B58" ref-type="bibr">Roiz-Valle et al., 2023</xref>), inflammation (<xref rid="B15" ref-type="bibr">Emmi et al., 2022</xref>), oxidative stress (<xref rid="B27" ref-type="bibr">Ib&#x000e1;&#x000f1;ez-Cabellos et al., 2023</xref>), apoptosis (<xref rid="B11" ref-type="bibr">Diakos et al., 2010</xref>), angiogenesis (<xref rid="B51" ref-type="bibr">Pencheva et al., 2012</xref>), and lipid metabolism (<xref rid="B14" ref-type="bibr">Elsakka et al., 2023</xref>). By regulating these processes, microRNAs can lead to the development or worsening of cardiovascular diseases. MicroRNAs also have potential to be used as diagnostic (<xref rid="B66" ref-type="bibr">Wang and Zhang, 2020</xref>) and therapeutic tools (<xref rid="B52" ref-type="bibr">Poller et al., 2018</xref>). Researchers have identified specific microRNAs that are dysregulated in cardiovascular diseases, and these microRNAs could be used as biomarkers for early diagnosis or disease monitoring. Additionally, by using drugs or gene therapies that target microRNAs that are not functioning properly (<xref rid="B30" ref-type="bibr">Kara et al., 2022</xref>), we may be able to treat heart and blood vessel problems more effectively in the future (<xref rid="B37" ref-type="bibr">Li and Rana, 2014</xref>).</p><p>In this review, we focus on microRNA-425 (miR-425), examining its biological dysregulation and therapeutic potential in cardiovascular diseases. By synthesizing current evidence, we highlight its role in disease pathogenesis, including aberrant signaling pathways and cellular dysfunction, and explore its emerging applications as a diagnostic biomarker and therapeutic target in cardiovascular medicine.</p></sec><sec id="s2"><title>2 The biological perturbation of MiR-425</title><sec id="s2-1"><title>2.1 Combined with LncRNAs to regulate biological function</title><p>Recent studies have found that miR-425 can work together with long non-coding RNAs to have additional control over various biological processes. This interaction between miR-425 and lncRNAs plays a role in regulating these functions within cells or organisms.</p><p>LncRNAs are long non-coding RNAs that have various functions in gene regulation, chromatin remodeling, and cellular differentiation. They are also involved in some diseases such as cancer, neurodegeneration, and cardiovascular disorders. One study found that a lncRNA called HHIP-AS1 promotes tumorigenicity by stabilizing a protein complex called dynein complex 1 in cancer prompt by SHH signaling pathway (<xref rid="B3" ref-type="bibr">Bartl et al., 2022</xref>). HHIP-AS1 binds directly to the mRNA of DYNC1I2, a component of dynein complex 1, and protects it from reduction by miR-425-5p. MSC-AS1 is a lncRNA that suppresses ovarian cancer by binding to miR-425-5p (<xref rid="B80" ref-type="bibr">Zhao et al., 2021</xref>). It negatively regulates miR-425-5p expression and affects its downstream targets such as CCND2 and BCL2. A third study found that miR-425-5p reduce two lncRNAs, MALAT1 and TUG1, and suppresses tumorigenesis (<xref rid="B73" ref-type="bibr">Yang et al., 2019</xref>). The latest study demonstrated that miR-425-5p modulates viral myocarditis through its interaction with lncRNA NEAT1 (17). The long non-coding RNA HCG22 emerged as a critical oncogenic modulator in papillary thyroid carcinoma (PTC), exerting profound influences on cellular dynamics through suppressive interactions with miR-425-5p. Mechanistic investigations revealed that HCG22 substantially enhanced neoplastic progression by modulating proliferative capacities and facilitating metastatic potential through targeted miRNA downregulation (<xref rid="B5" ref-type="bibr">Cao et al., 2024</xref>). These lncRNAs are one type of competing endogenous (ceRNAs) that can regulate miR-425-5p by this mechanism. Thus, miR-425 and lncRNAs form a complex interaction network that modulates cell proliferation in various cancers.</p><p>In addition to cell proliferation and migration, miR-425 has also been shown to interact with lncRNAs to regulate apoptosis, a process of programmed cell death. For example, miR-425-5p and the lncRNA MSC-AS1 have been found to interact in SKOV3 and A2780 cancer cells. When miR-425-5p is upregulated, it counteracts the overexpression of MSC-AS1. High levels of MSC-AS1 inhibit cell proliferation and promote cell apoptosis, highlighting the importance of their regulation in these cancer cell lines (<xref rid="B80" ref-type="bibr">Zhao et al., 2021</xref>). Another study found that lncRNA SNHG7 regulated the expression of TRAF5 by sponging miR-425-5p. TRAF5 is a key mediator of the NF-&#x003ba;B pathway, which plays a critical role in inflammation and apoptosis (<xref rid="B78" ref-type="bibr">Zhang et al., 2021</xref>). Lastly, during ischemic stroke, the long non-coding RNA Snhg8 plays a crucial role in reducing microglial inflammation. Snhg8 acts as a competitive endogenous RNA by binding to and sequestering miR-425-5p, the function is protective (<xref rid="B61" ref-type="bibr">Tian et al., 2021</xref>). Overall, these studies suggest that miR-425 and lncRNAs can work together to regulate biological functions, for example cell expansion, migration, and apoptosis. Further research into these interactions can promote the advancement of new therapies for disease.</p></sec><sec id="s2-2"><title>2.2 Binding with protein to regulate biological function</title><p>Another way in which miR-425 regulates biological function is by binding to specific proteins and modulating their expression or activity. MiR-425-5p has been found to improve liver damage. It Binding RIP1 mRNA to subdued the expression. Liver damage, RIP1-mediated necroptosis, IL-1&#x003b2;, and TNF-&#x003b1; were suppressed by miR-425-5p ago-miR but further aggravated by miR-425-5p antagomiR (<xref rid="B23" ref-type="bibr">Gu et al., 2020</xref>)). MiR-425-5p can binding TNF, ANXA2 in MSC cell. In addition, miR-425-5p enhanced osteoporosis in mice. MiR-425-5p might serve as a potential therapeutic target for the treatment of osteoporosis (<xref rid="B8" ref-type="bibr">Chen et al., 2021</xref>). According to this essay (<xref rid="B54" ref-type="bibr">Qi et al., 2019</xref>) MiR-425 is a novel strong regulator of adipogenesis and adipolysis in adipocytes. The literature (<xref rid="B62" ref-type="bibr">Tokarski et al., 2022</xref>) suggests that miR-425 directly regulate the expression of Hepatocyte growth factor (HGF) under hypoxia. HGFA is stimulate the proliferation and migration of endothelial cells. Come to conclusion that miR-425 is a crucial regulator in HGFA-HGF-c-Met signaling pathway. MiR-425-5p plays a pivotal role in modulating gemcitabine resistance through its intricate interactions within the MEF2A/SNHG16/NOTCH2 signaling axis, potentially offering novel insights into therapeutic strategies for chemoresistant malignancies (<xref rid="B85" ref-type="bibr">Zhou X. et al., 2024</xref>). MiR-425-5p emerges as a critical molecular regulator of bovine mammary epithelial cell (BMEC) proliferation, exerting its functional influence through precise modulation of the TOB2 signaling pathway. By targeting this specific molecular mechanism, the microRNA significantly contributes to cellular expansion and potentially provides insights into mammary gland development and function (<xref rid="B36" ref-type="bibr">Li et al., 2024</xref>).</p><p>These studies indicate miR-425 regulates cellular biological functions by binding with many target proteins. These proteins exhibit biological functions involved in apoptosis, angiogenesis, and metastasis regulation. The binding of miR-425 can directly inhibit the translation or degradation of these proteins, affecting cellular biological functions. These findings further demonstrate the important role of miR-425 in cellular biological processes and provide a new therapeutic approach to modulate these processes by regulating the of miR-425.</p></sec><sec id="s2-3"><title>2.3 Change the differentiation of immune cells to regulate biological functions</title><p>In osteoarthritis patients, miR-425 is involved in leukocyte migration, regulation of mitogen-activated protein (MAP) kinase tyrosine/serine/threonine phosphatase activity, interleukin-17 signaling pathway, and osteoclast differentiation, and can exert a strong influence on immune cell infiltration (<xref rid="B25" ref-type="bibr">Hua et al., 2022</xref>).</p><p>In Inflammatory bowel disease (IBD) (<xref rid="B74" ref-type="bibr">Yang et al., 2018</xref>), miR-425 play a role in the development of Th17 cells by targeting Foxo1. It means that increasing the levels of miR-425 (a type of small RNA molecule) in inflammatory bowel disease (IBD) can lead to the production of harmful Th17 cells by reducing the activity of a protein called Foxo1. The research has demonstrated that miR-425 hinders the growth of chronic lymphocytic leukemia (CLL) cells by controlling the activity of the Bruton&#x02019;s tyrosine kinase/phospholipase C&#x003b3;2 signaling pathway (<xref rid="B9" ref-type="bibr">Chen et al., 2020</xref>). Another literature states that (<xref rid="B70" ref-type="bibr">Wu et al., 2021</xref>) when miR-425 is high-expressed in diffuse large B cell lymphoma (DLBC) cells, it can lead to cells grow and divide. This can also increase their ability to form colonies. The differential association between the miR-425 and macrophage might be crucial for Colorectal cancer (CRC) (<xref rid="B47" ref-type="bibr">Ng et al., 2022</xref>). The article display that there was positive correlation between miR-425 and macrophages in CRC.</p></sec></sec><sec id="s3"><title>3 The role of biological disease markers</title><p>In neurological disorders (<xref rid="B42" ref-type="bibr">Manna et al., 2021</xref>) and diabetic retinopathy (<xref rid="B41" ref-type="bibr">Liu X. et al., 2022</xref>), miR-425 can also serve as a disease marker. Notably, miRNAs can be found in different bodily fluids like blood, saliva, and urine. This characteristic makes them valuable as biomarkers for the detection, prognosis, and treatment of various diseases.</p><p>One specific example of miR-425 in cancer is in metastatic prostate cancer (<xref rid="B57" ref-type="bibr">Rode et al., 2021</xref>; <xref rid="B55" ref-type="bibr">Rana et al., 2022</xref>). A study found that miR-425-5p as an exosomal biomarker. Research has indicated that miR-425 shows varying levels of expression in extracellular vesicles derived from both normal cells and prostate cancer cells. A study suggests that miR-425-5p can discriminated Progressive Supranuclear Paralysis from Parkinson&#x02019;s disease (<xref rid="B42" ref-type="bibr">Manna et al., 2021</xref>). A recent study found that serum miR-425-5p levels showed a gradual increasing trend in the healthy control group, the diabetic mellitus patients without diabetic retinopathy, and diabetic retinopathy patients. Moreover, the levels of miR-425-5p in proliferative DR (PDR) patients were elevated than that of non-PDR (NPDR) patients (<xref rid="B41" ref-type="bibr">Liu X. et al., 2022</xref>). Emerging evidence suggests that miR-425-5p, a pivotal microRNA implicated in programmed cell death mechanisms, demonstrates notable predictive potential in stratifying patients with esophageal squamous cell carcinoma (ESCC). The molecular signature of this specific miRNA offers promising insights into disease progression and potential diagnostic strategies (<xref rid="B82" ref-type="bibr">Zhidan et al., 2024</xref>).</p></sec><sec id="s4"><title>4 The clinical significance of MiR-425 in cardiovascular diseases</title><sec id="s4-1"><title>4.1 Reduces inflammation and heart repair</title><p>It has been reported that miR-196a-5p and miR-425-5p, which are found in exosomes derived from adipose-derived stem cells (ASC), can influence biological processes after a myocardial infarction. Both miRNAs were shown to prevent mitochondrial dysfunction and increase angiogenesis (<xref rid="B50" ref-type="bibr">Paiva and Agbulut, 2017</xref>), and polarize macrophages toward M2 (<xref rid="B10" ref-type="bibr">de Almeida Oliveira et al., 2022</xref>). A study found that miR-425 directly target receptor-interacting protein kinase 1 (RIPK1), and overexpression of miR-425 or knockdown of RIPK1. So miR-425 can become a promising therapeutic agent for treating heart injury by being activated by IR (<xref rid="B24" ref-type="bibr">Guo et al., 2020</xref>). Another study suggests that miR-425-3p is lowly expressed in viral myocarditis. Overexpression of miR-425-3p was found to improve cardiac function, alleviate pathological conditions. Additionally, miR-425-3p was found to bind to TGF-&#x003b2;1 and suppress its expression. These results suggest that overexpression of miR-425-3p can inhibit myocardial inflammation in mice with viral myocarditis (<xref rid="B35" ref-type="bibr">Li et al., 2021</xref>). In a research study (<xref rid="B7" ref-type="bibr">Chaudhari et al., 2023</xref>), the global expression patterns of miRNAs were analyzed in mouse ventricular tissue samples collected at different stages of postnatal development: postnatal day 1 (P01), P04, P09, and P23. The study discovered that miRNAs have a significant role in the development of the heart after birth and in the process of cardiac regeneration.</p><p>In summary, the findings from these studies indicate that miR-425 could be a promising therapeutic option for various treatments of heart disease by reducing inflammation (<xref rid="B77" ref-type="bibr">Zapata-Mart&#x000ed;nez et al., 2023</xref>), cardiac regeneration and promoting heart repair. However, additional research is necessary to gain a comprehensive understanding of how miR-425 functions and to investigate its potential clinical uses.</p></sec><sec id="s4-2"><title>4.2 Induce angiogenesis and improve the prediction of atherosclerosis</title><p>Understanding the intricate mechanisms underlying angiogenesis is essential for developing novel therapeutic strategies to target angiogenic disorders. Recently, miRNAs have been widely acknowledged for their involvement in a wide range of biological processes, including angiogenesis (<xref rid="B33" ref-type="bibr">Kir et al., 2018</xref>). Among these miRNAs, miRNA-425-5p has gained attention for its involvement in the complex orchestration of angiogenesis. Emerging evidence suggests that miRNA-425-5p acts as a crucial regulator of angiogenesis by modulating the activity of specific target genes in different stages of angiogenic process. Such as Spred1, SEPT7, and PDGFRA genes (<xref rid="B18" ref-type="bibr">Ferguson et al., 2018</xref>; <xref rid="B39" ref-type="bibr">Liu et al., 2021</xref>; <xref rid="B43" ref-type="bibr">McGeary et al., 2019</xref>). In a study, sodium arsenite (NaAsO2) was found to impede the formation of new blood vessels (angiogenesis). However, when miR-425-5p was over-expressed, the anti-angiogenic effects caused by NaAsO2 were reversed (<xref rid="B21" ref-type="bibr">Gao et al., 2016</xref>). Certain microRNAs, including miR-425-5p, were found to be abundant in exosomes derived from epidermal stem cells (EPSC-Exos). These microRNAs played a crucial role in suppressing the transformation of fibroblasts into myofibroblasts by reducing the expression of TGF-&#x003b2;1 in dermal fibroblasts. In summary, this study identified a new function of EPSC-Exos-specific microRNAs, indicating that miR-425-5p could be utilized as a potential strategy to prevent scar formation and angiogenesis during wound healing in clinical applications (<xref rid="B13" ref-type="bibr">Duan et al., 2020</xref>). Research (<xref rid="B32" ref-type="bibr">Kim et al., 2022</xref>) findings indicate that miR-425-5p, which is classified as an onco-miRNA, was detected within small extracellular vesicles (sEVs) that rely on syntenin-1 for their formation. These sEVs were observed to have an impact on cancer cell migration and angiogenesis.</p><p>Abnormal expression of miRNAs has been linked to the development and advancement of atherosclerosis (<xref rid="B60" ref-type="bibr">Sum and Brewer, 2023</xref>). A recent study (<xref rid="B49" ref-type="bibr">Ormseth et al., 2021</xref>) investigated the potential of miRNA-425 as a predictive biomarker for coronary atherosclerosis. The study included a group of rheumatoid arthritis (RA) patients with and without coronary atherosclerosis, as confirmed by angiography. Plasma samples were collected from the participants. The study findings demonstrated a significant increase in plasma levels of miRNA-425 among rheumatoid arthritis (RA) patients with coronary atherosclerosis, in comparison to those without the condition. Additionally, there was a positive correlation observed between the activity of miRNA-425 and the severity of coronary atherosclerosis, as assessed by angiographic findings. This suggests that miRNA-425 may contribute to the development of coronary atherosclerosis in the context of rheumatoid arthritis. Furthermore, the study assessed the diagnostic performance of plasma miRNA-425 for predicting coronary atherosclerosis in RA. ROC curve analysis show that miRNA-425 had good discriminatory power. These findings suggest that measuring plasma levels of miRNA-425 could enhance the accuracy of predicting coronary atherosclerosis in individuals with rheumatoid arthritis.</p></sec><sec id="s4-3"><title>4.3 Reduces cardiac fibrosis</title><p>In a specific study (<xref rid="B67" ref-type="bibr">Wang et al., 2023</xref>), a comprehensive analysis identified a total of 18 miRNAs targeted in human atrial appendage tissues. In another study (<xref rid="B69" ref-type="bibr">Wei et al., 2022</xref>), the researchers examined the involvement of miR-425-5p in atrial fibrillation (AF) and investigated its effects on atrial fibrosis and remodeling. The study revealed that miR-425-5p level was significantly downregulated in AF patients compared to those without AF. Further mechanistic investigations demonstrated that miR-425-5p inhibits the expression of CREB1 in atrial cells. CREB1 is a transcription factor involved in various cellular processes, including fibrosis and remodeling. The decreased expression of miR-425-5p in atrial fibrillation (AF) results in elevated levels of CREB1, promoting atrial fibrosis and remodeling. Functional experiments utilizing animal models of AF confirmed the regulatory role in atrial fibrosis and remodeling. Overexpression resulted in decreased fibrosis and improved atrial electrical conduction properties, while downregulation had the opposite effect. Complementary investigative evidence demonstrates that fibroblast-originated compact regulatory ribonucleic acid sequences (miR-425-5p) attenuates transverse aortic constriction-mediated cardiac dysfunction, positioning this molecular marker as a promising diagnostic and interventional strategy for managing advanced cardiac insufficiency pathologies (<xref rid="B83" ref-type="bibr">Zhou H. et al., 2024</xref>).</p><p>In summary, above results establishes miR-425-5p as a negative regulator of atrial fibrosis and a promoter of atrial remodeling. It suggests that the decreased level of miR-425-5p in AF contributes to the progression of atrial fibrosis and highlights the importance of targeting miR-425-5p and its downstream target CREB1 as potential therapeutic strategies for AF. By modulating miR-425-5p levels, it may be possible to mitigate atrial fibrosis and prevent the adverse remodeling processes associated with AF, ultimately leading to improved management and treatment of this prevalent cardiac arrhythmia. Further research is warranted to explore the translational potential of miR-425-5p as a therapeutic target in AF.</p></sec><sec id="s4-4"><title>4.4 Regulating atrial natriuretic peptide affects cardiovascular function</title><p>Atrial natriuretic peptide (ANP) is essential for maintaining cardiovascular equilibrium by controlling blood pressure, fluid balance, and electrolyte levels. Recent studies have identified miR-425 as a negative regulator of ANP (<xref rid="B2" ref-type="bibr">Arora et al., 2013</xref>). ANP is synthesized and released in response to increased cardiac wall tension, which occurs during conditions such as hypertension, heart failure, or volume overload. Once released, ANP acts on target tissues, primarily the kidneys, to induce natriuresis (sodium excretion) and diuresis (increased urine production), thereby reducing blood volume and blood pressure. ANP also inhibits the secretion of renin and aldosterone, further contributing to blood pressure regulation. In a study (<xref rid="B64" ref-type="bibr">Vandenwijngaert et al., 2018</xref>) conducted on rat models of heart failure, an elevated expression of miR-425 was observed in hearts experiencing heart failure. Overexpression of miR-425 resulted in decreased ANP expression and secretion. Similar findings were observed in human cardiac tissues, suggesting the conservation of miR-425-mediated regulation across species. The dysregulation of ANP expression is associated with various cardiovascular diseases. The identification of miR-425 suggests a potential therapeutic target for these conditions. Modulating miR-425 levels or targeting its downstream effectors may offer a novel approach to enhance ANP production and its beneficial effects on cardiovascular function. MiRNA-425 has emerged as a key regulator of ANP expression and secretion. Its upregulation in heart failure and its ability to decrease ANP levels indicate its involvement in cardiovascular pathology. Understanding the mechanisms underlying miR-425-mediated regulation of ANP may pave the way for the development of novel therapeutic strategies targeting the ANP pathway. Additional research is required to fully investigate the extent of miR-425 modulation in cardiovascular physiology and its clinical implications in the management of cardiovascular diseases.</p></sec></sec><sec id="s5"><title>5 Target gene prediction and KEGG enrichment analysis</title><p>Target gene prediction and KEGG enrichment analysis can be conducted to gain insights into the function and pathways influenced by miRNAs. Here, we will outline the process of target gene prediction and the subsequent KEGG enrichment analysis for miR-425. Several computational tools and databases are available for predicting miRNA target genes. Some commonly used tools include TargetScan, miRanda, and miRDB. These tools utilize algorithms that consider sequence complementarity between the miRNA and the mRNA, as well as other features such as conservation across species and the presence of 3&#x02032;UTR. To predict target genes for miR-425, we input miR-425 into TargetScan and miRDB, take the intersection, and predict a total of 247 target genes. We then used the R package &#x0201c;clusterProfiler, enrichplot, ggplot2, pathview, ggnewscale, DOSE&#x0201d; for KEGG enrichment analysis and obtained <xref rid="F1" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Target Gene prediction and KEGG enrichment analysis.</p></caption><graphic xlink:href="fcell-13-1593241-g001" position="float"/></fig></sec><sec id="s6"><title>6 Conclusion and perspectives</title><p>As illustrated in <xref rid="F1" ref-type="fig">Figure 1</xref> and <xref rid="T1" ref-type="table">Table 1</xref>, miR-425 may exert its biological functions by interfering with the expression of key genes in several common pathways. Notably, the relatively large circle in the Cellular senescence pathway indicates that miR-425 likely plays a significant role in this pathway among those depicted. Through literature review, we found confirmatory evidence of this relationship in a study demonstrating that miR-425-5p inhibits Crebzf to regulate oocyte senescence via chromatin modification (<xref rid="B29" ref-type="bibr">Jueraitetibaike et al., 2024</xref>). Although Crebzf was not identified among the key genes shown on the left side of <xref rid="F1" ref-type="fig">Figure 1</xref>, the gene network presented provides a broad spectrum of potential research targets. For instance, <xref rid="F1" ref-type="fig">Figure 1</xref> depicts a connection between NRAS and Cellular senescence. Our literature analysis revealed that titration of RAS alters senescence states and influences tumor initiation, with NRAS being one of the most common members of the RAS family (<xref rid="B6" ref-type="bibr">Chan et al., 2024</xref>). Integrating the findings from <xref rid="F1" ref-type="fig">Figure 1</xref> with these two studies suggests a hypothesis that miR-425 may influence disease progression through NRAS-mediated cellular senescence. In this manner, <xref rid="F1" ref-type="fig">Figure 1</xref> serves as a valuable source of research inspiration.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>MiR-425 in cardiovascular diseases.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Roles</th><th align="left" rowspan="1" colspan="1">Cardiovascular diseases</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" colspan="1">Reduces inflammation</td><td align="left" rowspan="1" colspan="1">After myocardial infarction, polarize macrophages toward the anti-inflammatory M2 immunophenotype<break/>directly target receptor-interacting protein kinase 1 (RIPK1) attenuate inflammation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B10" ref-type="bibr">de Almeida Oliveira et al. (2022)</xref>
<break/>(<xref rid="B24" ref-type="bibr">Guo et al., 2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Interaction with TGF-&#x003b2;1 reduce viral myocarditis decrease<break/>Interaction with lncRNA NEAT1 reduce viral myocarditis decrease</td><td align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Li et al. (2021)</xref>
<break/>(<xref rid="B20" ref-type="bibr">Gao et al., 2024</xref>)</td></tr><tr><td rowspan="3" align="left" colspan="1">Induction of angiogenesis</td><td align="left" rowspan="1" colspan="1">Target cerebral cavernous malformation 3 (CCM3)</td><td align="left" rowspan="1" colspan="1">
<xref rid="B21" ref-type="bibr">Gao et al. (2016)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevent scar formation and angiogenesis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B13" ref-type="bibr">Duan et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">As onco-miRNA promote cancer cell migration and angiogenesis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B32" ref-type="bibr">Kim et al. (2022)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Prediction of diseases</td><td align="left" rowspan="1" colspan="1">Predictive biomarker for coronary atherosclerosis in patients with rheumatoid arthritis<break/>markers for diagnosing heart failure</td><td align="left" rowspan="1" colspan="1">
<xref rid="B49" ref-type="bibr">Ormseth et al. (2021)</xref>
<break/>(<xref rid="B81" ref-type="bibr">Zheng et al., 2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reduces cardiac fibrosis</td><td align="left" rowspan="1" colspan="1">Inhibits the expression of CREB1 in atrial cells promoting atrial fibrosis and remodeling<break/>Alleviates cardiac remodelling in heart failure</td><td align="left" rowspan="1" colspan="1">
<xref rid="B69" ref-type="bibr">Wei et al. (2022)</xref>
<break/>(<xref rid="B83" ref-type="bibr">Zhou et al., 2024b</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulating ANP</td><td align="left" rowspan="1" colspan="1">Negative regulator of ANP</td><td align="left" rowspan="1" colspan="1">
<xref rid="B2" ref-type="bibr">Arora et al. (2013)</xref>, <xref rid="B64" ref-type="bibr">Vandenwijngaert et al. (2018)</xref>
</td></tr></tbody></table></table-wrap><p>Through the above sections, miR-425 has been identified as a significant contributor to the development and progression of cardiovascular diseases, including heart failure, hypertension, atherosclerosis, and cardiac remodeling. Its dysregulation contributes to the progression of these diseases through its effects on various molecular pathways involved in cardiac function, vascular remodeling, and endothelial dysfunction.</p><p>The dysregulation of miR-425 expression in cardiovascular diseases opens up new avenues for its potential use as a diagnostic biomarker. Circulating levels of miR-425 in plasma or serum have shown correlations with disease severity, treatment response, and clinical outcomes. Utilizing miR-425 as a non-invasive biomarker could enhance early detection, risk stratification, and monitoring of cardiovascular diseases, ultimately leading to improved patient management and outcomes. Furthermore, targeting miR-425 holds promise for developing novel therapeutic strategies. Inhibition of miR-425 using antimiR oligonucleotides or viral vectors expressing competing endogenous RNAs (ceRNAs) has shown promising results in preclinical studies. By suppressing the activity of miR-425, it is possible to improve cardiac function, attenuate cardiac remodeling, and ameliorate hypertension. However, it is crucial to further optimize the delivery methods, ensure target specificity, and evaluate the long-term safety and efficacy of miR-425-based therapies before translation into clinical applications. The role and prospects of miR-425 in cardiovascular disease highlight the growing importance of understanding the intricate regulatory mechanisms involved in cardiac pathophysiology. Further research is needed to elucidate the precise molecular targets and signaling pathways influenced by miR-425, as well as to investigate potential synergistic effects with existing therapeutic approaches.</p><p>In brief, miR-425 represents a promising area of study for researchers and clinicians in the field of cardiovascular medicine. Continued investigations into its role, diagnostic potential, and therapeutic applications will deepen our understanding of cardiovascular diseases (<xref rid="B46" ref-type="bibr">Mota et al., 2023</xref>) and potentially lead to the development of innovative approaches for disease management and treatment.</p></sec></body><back><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>SZ: Writing &#x02013; original draft. BH: Writing &#x02013; review and editing, Supervision.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altman</surname><given-names>J.</given-names></name><name><surname>Jones</surname><given-names>G.</given-names></name><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>Tear film MicroRNAs as potential biomarkers: a review</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>24</volume> (<issue>4</issue>), <fpage>3694</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24043694</pub-id>
<pub-id pub-id-type="pmid">36835108</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arora</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>A. M.</given-names></name><name><surname>Bloch</surname><given-names>D. B.</given-names></name><name><surname>Davis-Dusenbery</surname><given-names>B. N.</given-names></name><name><surname>Ghorbani</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Atrial natriuretic peptide is negatively regulated by microRNA-425</article-title>. <source>J. Clin. Invest</source>
<volume>123</volume> (<issue>8</issue>), <fpage>3378</fpage>&#x02013;<lpage>3382</lpage>. <pub-id pub-id-type="doi">10.1172/JCI67383</pub-id>
<pub-id pub-id-type="pmid">23867623</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartl</surname><given-names>J.</given-names></name><name><surname>Zanini</surname><given-names>M.</given-names></name><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Forget</surname><given-names>A.</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>L.</given-names></name><name><surname>Talbot</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors</article-title>. <source>Nat. Commun.</source>
<volume>13</volume> (<issue>1</issue>), <fpage>4061</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-31574-z</pub-id>
<pub-id pub-id-type="pmid">35831316</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name></person-group> (<year>2024</year>). <article-title>lncRNA HCG22 regulated cell growth and metastasis of papillary thyroid cancer via negatively modulating miR-425-5p</article-title>. <source>Endokrynol. Pol.</source>
<volume>75</volume> (<issue>1</issue>), <fpage>20</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.5603/ep.97425</pub-id>
<pub-id pub-id-type="pmid">38497386</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chan</surname><given-names>A. S. L.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Narita</surname><given-names>M.</given-names></name><name><surname>Cassidy</surname><given-names>L. D.</given-names></name><name><surname>Young</surname><given-names>A. R. J.</given-names></name><name><surname>Bermejo-Rodriguez</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Titration of RAS alters senescent state and influences tumour initiation</article-title>. <source>Nature</source>
<volume>633</volume> (<issue>8030</issue>), <fpage>678</fpage>&#x02013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-07797-z</pub-id>
<pub-id pub-id-type="pmid">39112713</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaudhari</surname><given-names>U.</given-names></name><name><surname>Pohjolainen</surname><given-names>L.</given-names></name><name><surname>Ruskoaho</surname><given-names>H.</given-names></name><name><surname>Talman</surname><given-names>V.</given-names></name></person-group> (<year>2023</year>). <article-title>Genome-wide profiling of miRNA-gene regulatory networks in mouse postnatal heart development-implications for cardiac regeneration</article-title>. <source>Front. Cardiovasc Med.</source>
<volume>10</volume>, <fpage>1148618</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2023.1148618</pub-id>
<pub-id pub-id-type="pmid">37283582</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>MicroRNA-425-5p modulates osteoporosis by targeting annexin A2</article-title>. <source>Immun. Ageing</source>
<volume>18</volume> (<issue>1</issue>), <fpage>45</fpage>. <pub-id pub-id-type="doi">10.1186/s12979-021-00256-7</pub-id>
<pub-id pub-id-type="pmid">34879879</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>MicroRNA-425 inhibits proliferation of chronic lymphocytic leukaemia cells through regulation of the Bruton's tyrosine kinase/phospholipase C&#x003b3;2 signalling pathway</article-title>. <source>Exp. Ther. Med.</source>
<volume>20</volume> (<issue>2</issue>), <fpage>1169</fpage>&#x02013;<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2020.8771</pub-id>
<pub-id pub-id-type="pmid">32742355</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Almeida Oliveira</surname><given-names>N. C.</given-names></name><name><surname>Neri</surname><given-names>E. A.</given-names></name><name><surname>Silva</surname><given-names>C. M.</given-names></name><name><surname>Valad&#x000e3;o</surname><given-names>I. C.</given-names></name><name><surname>Fonseca-Alaniz</surname><given-names>M. H.</given-names></name><name><surname>Zogbi</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Multicellular regulation of miR-196a-5p and miR-425-5 from adipose stem cell-derived exosomes and cardiac repair</article-title>. <source>Clin. Sci. (Lond).</source>
<volume>136</volume> (<issue>17</issue>), <fpage>1281</fpage>&#x02013;<lpage>1301</lpage>. <pub-id pub-id-type="doi">10.1042/CS20220216</pub-id>
<pub-id pub-id-type="pmid">35894060</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diakos</surname><given-names>C.</given-names></name><name><surname>Zhong</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Vasconcelos</surname><given-names>G. M.</given-names></name><name><surname>Krapf</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a</article-title>. <source>Blood</source>
<volume>116</volume> (<issue>23</issue>), <fpage>4885</fpage>&#x02013;<lpage>4893</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-02-206706</pub-id>
<pub-id pub-id-type="pmid">20807887</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diener</surname><given-names>C.</given-names></name><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Meese</surname><given-names>E.</given-names></name></person-group> (<year>2022</year>). <article-title>Emerging concepts of miRNA therapeutics: from cells to clinic</article-title>. <source>Trends Genet.</source>
<volume>38</volume> (<issue>6</issue>), <fpage>613</fpage>&#x02013;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2022.02.006</pub-id>
<pub-id pub-id-type="pmid">35303998</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duan</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Epidermal stem cell-derived exosomes promote skin regeneration by downregulating transforming growth factor-&#x003b2;1 in wound healing</article-title>. <source>Stem Cell Res. Ther.</source>
<volume>11</volume> (<issue>1</issue>), <fpage>452</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-020-01971-6</pub-id>
<pub-id pub-id-type="pmid">33097078</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elsakka</surname><given-names>E. G. E.</given-names></name><name><surname>Abulsoud</surname><given-names>A. I.</given-names></name><name><surname>El-Mahdy</surname><given-names>H. A.</given-names></name><name><surname>Ismail</surname><given-names>A.</given-names></name><name><surname>Elballal</surname><given-names>M. S.</given-names></name><name><surname>Mageed</surname><given-names>S. S. A.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>miRNAs orchestration of cardiovascular diseases - particular emphasis on diagnosis, and progression</article-title>. <source>Pathol. Res. Pract.</source>
<volume>248</volume>, <fpage>154613</fpage>. <pub-id pub-id-type="doi">10.1016/j.prp.2023.154613</pub-id>
<pub-id pub-id-type="pmid">37327567</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emmi</surname><given-names>G.</given-names></name><name><surname>Bagni</surname><given-names>G.</given-names></name><name><surname>Lastraioli</surname><given-names>E.</given-names></name><name><surname>Di Patti</surname><given-names>F.</given-names></name><name><surname>Bettiol</surname><given-names>A.</given-names></name><name><surname>Fiorillo</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A unique circulating miRNA profile highlights thrombo-inflammation in Beh&#x000e7;et's syndrome</article-title>. <source>Ann. Rheum. Dis.</source>
<volume>81</volume> (<issue>3</issue>), <fpage>386</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2021-220859</pub-id>
<pub-id pub-id-type="pmid">34844932</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ergin</surname><given-names>K.</given-names></name><name><surname>&#x000c7;etinkaya</surname><given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Regulation of MicroRNAs</article-title>. <source>Methods Mol. Biol.</source>
<volume>2257</volume>, <fpage>1</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-1170-8_1</pub-id>
<pub-id pub-id-type="pmid">34432271</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Inflammatory memory-activated biomimetic nanovesicles regulate neutrophil plasticity and metabolic reprogramming for rapid diabetic wound healing via targeting miR-193a-5p/TLR4/JNK/P38 MAPK pathways</article-title>. <source>J. Nanobiotechnology</source>
<volume>23</volume> (<issue>1</issue>), <fpage>115</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-025-03193-5</pub-id>
<pub-id pub-id-type="pmid">39962468</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>S. W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>C. J.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Neelamegham</surname><given-names>S.</given-names></name><name><surname>Canty</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The microRNA regulatory landscape of MSC-derived exosomes: a systems view</article-title>. <source>Sci. Rep.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>1419</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-19581-x</pub-id>
<pub-id pub-id-type="pmid">29362496</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gan</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Xie</surname><given-names>D.</given-names></name><name><surname>Bond Lau</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Christopher</surname><given-names>T. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Ischemic heart-derived small extracellular vesicles impair adipocyte function</article-title>. <source>Circ. Res.</source>
<volume>130</volume> (<issue>1</issue>), <fpage>48</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.320157</pub-id>
<pub-id pub-id-type="pmid">34763521</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Ma</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Diagnostic value and clinical significance of lncRNA NEAT1 combined with miR-425-3p in children with viral myocarditis</article-title>. <source>Turk J. Pediatr.</source>
<volume>66</volume> (<issue>4</issue>), <fpage>439</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.24953/turkjpediatr.2024.4579</pub-id>
<pub-id pub-id-type="pmid">39387427</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Arsenic-induced anti-angiogenesis via miR-425-5p-regulated CCM3</article-title>. <source>Toxicol. Lett.</source>
<volume>254</volume>, <fpage>22</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2016.04.023</pub-id>
<pub-id pub-id-type="pmid">27132035</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goto</surname><given-names>Y.</given-names></name><name><surname>Suga</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>The RaPID platform for the discovery of pseudo-natural macrocyclic peptides</article-title>. <source>Acc. Chem. Res.</source>
<volume>54</volume> (<issue>18</issue>), <fpage>3604</fpage>&#x02013;<lpage>3617</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.1c00391</pub-id>
<pub-id pub-id-type="pmid">34505781</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>C.</given-names></name><name><surname>Hou</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>miR-425-5p improves inflammation and septic liver damage through negatively regulating the RIP1-mediated necroptosis</article-title>. <source>Inflamm. Res.</source>
<volume>69</volume> (<issue>3</issue>), <fpage>299</fpage>&#x02013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-020-01321-5</pub-id>
<pub-id pub-id-type="pmid">32002587</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Wen</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425</article-title>. <source>Biomed. Pharmacother.</source>
<volume>125</volume>, <fpage>109784</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.109784</pub-id>
<pub-id pub-id-type="pmid">32092815</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hua</surname><given-names>S. L.</given-names></name><name><surname>Liang</surname><given-names>J. Q.</given-names></name><name><surname>Hu</surname><given-names>G. F.</given-names></name><name><surname>Yang</surname><given-names>X. R.</given-names></name><name><surname>Fang</surname><given-names>D. L.</given-names></name><name><surname>Lu</surname><given-names>J. L.</given-names></name></person-group> (<year>2022</year>). <article-title>Constructing a competing endogenous RNA network for osteoarthritis</article-title>. <source>Ann. Transl. Med.</source>
<volume>10</volume> (<issue>3</issue>), <fpage>147</fpage>. <pub-id pub-id-type="doi">10.21037/atm-21-6711</pub-id>
<pub-id pub-id-type="pmid">35284549</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hua</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Pentaparthi</surname><given-names>S. R.</given-names></name><name><surname>McGrail</surname><given-names>D. J.</given-names></name><name><surname>Zou</surname><given-names>R.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Landscape of MicroRNA regulatory network architecture and functional rerouting in cancer</article-title>. <source>Cancer Res.</source>
<volume>83</volume> (<issue>1</issue>), <fpage>59</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0371</pub-id>
<pub-id pub-id-type="pmid">36265133</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ib&#x000e1;&#x000f1;ez-Cabellos</surname><given-names>J. S.</given-names></name><name><surname>Pallard&#x000f3;</surname><given-names>F. V.</given-names></name><name><surname>Garc&#x000ed;a-Gim&#x000e9;nez</surname><given-names>J. L.</given-names></name><name><surname>Seco-Cervera</surname><given-names>M.</given-names></name></person-group> (<year>2023</year>). <article-title>Oxidative stress and epigenetics: miRNA involvement in rare autoimmune diseases</article-title>. <source>Antioxidants (Basel).</source>
<volume>12</volume> (<issue>4</issue>), <fpage>800</fpage>. <pub-id pub-id-type="doi">10.3390/antiox12040800</pub-id>
<pub-id pub-id-type="pmid">37107175</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jueraitetibaike</surname><given-names>K.</given-names></name><name><surname>Tang</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>MiR-425-5p suppression of Crebzf regulates oocyte aging via chromatin modification</article-title>. <source>Geroscience</source>
<volume>46</volume> (<issue>4</issue>), <fpage>3723</fpage>&#x02013;<lpage>3742</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-023-00875-6</pub-id>
<pub-id pub-id-type="pmid">37532927</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kara</surname><given-names>G.</given-names></name><name><surname>Calin</surname><given-names>G. A.</given-names></name><name><surname>Ozpolat</surname><given-names>B.</given-names></name></person-group> (<year>2022</year>). <article-title>RNAi-based therapeutics and tumor targeted delivery in cancer</article-title>. <source>Adv. Drug Deliv. Rev.</source>
<volume>182</volume>, <fpage>114113</fpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2022.114113</pub-id>
<pub-id pub-id-type="pmid">35063535</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karvinen</surname><given-names>S.</given-names></name><name><surname>Siev&#x000e4;nen</surname><given-names>T.</given-names></name><name><surname>Karppinen</surname><given-names>J. E.</given-names></name><name><surname>Hautasaari</surname><given-names>P.</given-names></name><name><surname>Bart</surname><given-names>G.</given-names></name><name><surname>Samoylenko</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>MicroRNAs in extracellular vesicles in sweat change in response to endurance exercise</article-title>. <source>Front. Physiol.</source>
<volume>11</volume>, <fpage>676</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2020.00676</pub-id>
<pub-id pub-id-type="pmid">32760282</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>O.</given-names></name><name><surname>Hwangbo</surname><given-names>C.</given-names></name><name><surname>Tran</surname><given-names>P. T.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name></person-group> (<year>2022</year>). <article-title>Syntenin-1-mediated small extracellular vesicles promotes cell growth, migration, and angiogenesis by increasing onco-miRNAs secretion in lung cancer cells</article-title>. <source>Cell Death Dis.</source>
<volume>13</volume> (<issue>2</issue>), <fpage>122</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-04594-2</pub-id>
<pub-id pub-id-type="pmid">35136055</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kir</surname><given-names>D.</given-names></name><name><surname>Schnettler</surname><given-names>E.</given-names></name><name><surname>Modi</surname><given-names>S.</given-names></name><name><surname>Ramakrishnan</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Regulation of angiogenesis by microRNAs in cardiovascular diseases</article-title>. <source>Angiogenesis</source>
<volume>21</volume> (<issue>4</issue>), <fpage>699</fpage>&#x02013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1007/s10456-018-9632-7</pub-id>
<pub-id pub-id-type="pmid">29956018</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kontidou</surname><given-names>E.</given-names></name><name><surname>Collado</surname><given-names>A.</given-names></name><name><surname>Pernow</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name></person-group> (<year>2023</year>). <article-title>Erythrocyte-derived microRNAs: emerging players in cardiovascular and metabolic disease</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>43</volume> (<issue>5</issue>), <fpage>628</fpage>&#x02013;<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.123.319027</pub-id>
<pub-id pub-id-type="pmid">36924230</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Tu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>MicroRNA-425-3p inhibits myocardial inflammation and cardiomyocyte apoptosis in mice with viral myocarditis through targeting TGF-&#x003b2;1</article-title>. <source>Immun. Inflamm. Dis.</source>
<volume>9</volume> (<issue>1</issue>), <fpage>288</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">33332750</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>miR-425-5p regulates proliferation of bovine mammary epithelial cells by targeting TOB2</article-title>. <source>Genes (Basel)</source>
<volume>15</volume> (<issue>2</issue>), <fpage>174</fpage>. <pub-id pub-id-type="doi">10.3390/genes15020174</pub-id>
<pub-id pub-id-type="pmid">38397164</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Rana</surname><given-names>T. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Therapeutic targeting of microRNAs: current status and future challenges</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>13</volume> (<issue>8</issue>), <fpage>622</fpage>&#x02013;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4359</pub-id>
<pub-id pub-id-type="pmid">25011539</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Lock</surname><given-names>R.</given-names></name><name><surname>Nash</surname><given-names>T.</given-names></name><name><surname>Vunjak-Novakovic</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Cell type-specific microRNA therapies for myocardial infarction</article-title>. <source>Sci. Transl. Med.</source>
<volume>13</volume> (<issue>580</issue>), <fpage>eabd0914</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abd0914</pub-id>
<pub-id pub-id-type="pmid">33568517</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>MicroRNA-425-5p is involved in the development of diabetic retinopathy and regulates the proliferation and migration of retinal microvascular endothelial cells</article-title>. <source>Ophthalmic Res.</source>
<volume>65</volume> (<issue>1</issue>), <fpage>60</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1159/000516906</pub-id>
<pub-id pub-id-type="pmid">34571504</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manna</surname><given-names>I.</given-names></name><name><surname>Quattrone</surname><given-names>A.</given-names></name><name><surname>De Benedittis</surname><given-names>S.</given-names></name><name><surname>Vescio</surname><given-names>B.</given-names></name><name><surname>Iaccino</surname><given-names>E.</given-names></name><name><surname>Quattrone</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: a pilot study</article-title>. <source>Park. Relat. Disord.</source>
<volume>93</volume>, <fpage>77</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2021.11.020</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGeary</surname><given-names>S. E.</given-names></name><name><surname>Lin</surname><given-names>K. S.</given-names></name><name><surname>Shi</surname><given-names>C. Y.</given-names></name><name><surname>Pham</surname><given-names>T. M.</given-names></name><name><surname>Bisaria</surname><given-names>N.</given-names></name><name><surname>Kelley</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The biochemical basis of microRNA targeting efficacy</article-title>. <source>Science.</source>
<volume>366</volume> (<issue>6472</issue>), <fpage>eaav1741</fpage>. <pub-id pub-id-type="doi">10.1126/science.aav1741</pub-id>
<pub-id pub-id-type="pmid">31806698</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Current status and trends in small nucleic acid drug development: leading the future</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>14</volume> (<issue>9</issue>), <fpage>3802</fpage>&#x02013;<lpage>3817</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2024.05.008</pub-id>
<pub-id pub-id-type="pmid">39309508</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michell</surname><given-names>D. L.</given-names></name><name><surname>Vickers</surname><given-names>K. C.</given-names></name></person-group> (<year>2016</year>). <article-title>HDL and microRNA therapeutics in cardiovascular disease</article-title>. <source>Pharmacol. Ther.</source>
<volume>168</volume>, <fpage>43</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.09.001</pub-id>
<pub-id pub-id-type="pmid">27595929</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mota</surname><given-names>G. A. F.</given-names></name><name><surname>Gatto</surname><given-names>M.</given-names></name><name><surname>Gregolin</surname><given-names>C. S.</given-names></name><name><surname>Souza</surname><given-names>S. L. B.</given-names></name><name><surname>Okoshi</surname><given-names>M. P.</given-names></name></person-group> (<year>2023</year>). <article-title>mRNA, miRNA, lncRNA, ceRNA: the future of cardiovascular research?</article-title>
<source>Arq. Bras. Cardiol.</source>
<volume>120</volume> (<issue>4</issue>), <fpage>e20230209</fpage>. <pub-id pub-id-type="doi">10.36660/abc.20230209</pub-id>
<pub-id pub-id-type="pmid">37194755</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wan</surname><given-names>T. M.</given-names></name><name><surname>Iyer</surname><given-names>D.</given-names></name><name><surname>Sin</surname><given-names>R. W.</given-names></name><name><surname>Lo</surname><given-names>O. S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Investigation of miRNA dysregulation and association with immune cell profile during malignant transformation of colorectal cells</article-title>. <source>Eur. J. Surg. Oncol.</source>
<volume>48</volume> (<issue>1</issue>), <fpage>245</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2021.09.016</pub-id>
<pub-id pub-id-type="pmid">34620510</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noh</surname><given-names>M. Y.</given-names></name><name><surname>Kwon</surname><given-names>M. S.</given-names></name><name><surname>Oh</surname><given-names>K. W.</given-names></name><name><surname>Nahm</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>H. K.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>miRNA-214 to predict progression and survival in ALS</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>. <pub-id pub-id-type="doi">10.1136/jnnp-2024-335177</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ormseth</surname><given-names>M. J.</given-names></name><name><surname>Solus</surname><given-names>J. F.</given-names></name><name><surname>Sheng</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>S. C.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Plasma miRNAs improve the prediction of coronary atherosclerosis in patients with rheumatoid arthritis</article-title>. <source>Clin. Rheumatol.</source>
<volume>40</volume> (<issue>6</issue>), <fpage>2211</fpage>&#x02013;<lpage>2219</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-020-05573-8</pub-id>
<pub-id pub-id-type="pmid">33389220</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paiva</surname><given-names>S.</given-names></name><name><surname>Agbulut</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>MiRroring the multiple potentials of MicroRNAs in acute myocardial infarction</article-title>. <source>Front. Cardiovasc Med.</source>
<volume>4</volume>, <fpage>73</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2017.00073</pub-id>
<pub-id pub-id-type="pmid">29209617</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pencheva</surname><given-names>N.</given-names></name><name><surname>Tran</surname><given-names>H.</given-names></name><name><surname>Buss</surname><given-names>C.</given-names></name><name><surname>Huh</surname><given-names>D.</given-names></name><name><surname>Drobnjak</surname><given-names>M.</given-names></name><name><surname>Busam</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis</article-title>. <source>Cell</source>
<volume>151</volume> (<issue>5</issue>), <fpage>1068</fpage>&#x02013;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.10.028</pub-id>
<pub-id pub-id-type="pmid">23142051</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poller</surname><given-names>W.</given-names></name><name><surname>Dimmeler</surname><given-names>S.</given-names></name><name><surname>Heymans</surname><given-names>S.</given-names></name><name><surname>Zeller</surname><given-names>T.</given-names></name><name><surname>Haas</surname><given-names>J.</given-names></name><name><surname>Karakas</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives</article-title>. <source>Eur. Heart J.</source>
<volume>39</volume> (<issue>29</issue>), <fpage>2704</fpage>&#x02013;<lpage>2716</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehx165</pub-id>
<pub-id pub-id-type="pmid">28430919</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Przybyci&#x00144;ski</surname><given-names>J.</given-names></name><name><surname>Czerewaty</surname><given-names>M.</given-names></name><name><surname>Kwiatkowska</surname><given-names>E.</given-names></name><name><surname>Dziedziejko</surname><given-names>V.</given-names></name><name><surname>Safranow</surname><given-names>K.</given-names></name><name><surname>Doma&#x00144;ski</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>MicroRNAs miR-148a-3p, miR-425-3p, and miR-20a-5p in patients with IgA nephropathy</article-title>. <source>Genes (Basel)</source>
<volume>16</volume> (<issue>2</issue>), <fpage>125</fpage>. <pub-id pub-id-type="doi">10.3390/genes16020125</pub-id>
<pub-id pub-id-type="pmid">40004454</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>MicroRNA-425 controls lipogenesis and lipolysis in adipocytes</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Biol. Lipids</source>
<volume>1864</volume> (<issue>5</issue>), <fpage>744</fpage>&#x02013;<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2019.02.007</pub-id>
<pub-id pub-id-type="pmid">30822529</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rana</surname><given-names>S.</given-names></name><name><surname>Valbuena</surname><given-names>G. N.</given-names></name><name><surname>Curry</surname><given-names>E.</given-names></name><name><surname>Bevan</surname><given-names>C. L.</given-names></name><name><surname>Keun</surname><given-names>H. C.</given-names></name></person-group> (<year>2022</year>). <article-title>MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data</article-title>. <source>Br. J. Cancer</source>
<volume>126</volume> (<issue>3</issue>), <fpage>502</fpage>&#x02013;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1038/s41416-021-01677-3</pub-id>
<pub-id pub-id-type="pmid">35022525</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rode</surname><given-names>M. P.</given-names></name><name><surname>Silva</surname><given-names>A. H.</given-names></name><name><surname>Cisilotto</surname><given-names>J.</given-names></name><name><surname>Rosolen</surname><given-names>D.</given-names></name><name><surname>Creczynski-Pasa</surname><given-names>T. B.</given-names></name></person-group> (<year>2021</year>). <article-title>miR-425-5p as an exosomal biomarker for metastatic prostate cancer</article-title>. <source>Cell Signal</source>
<volume>87</volume>, <fpage>110113</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2021.110113</pub-id>
<pub-id pub-id-type="pmid">34371055</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roiz-Valle</surname><given-names>D.</given-names></name><name><surname>Caravia</surname><given-names>X. M.</given-names></name><name><surname>L&#x000f3;pez-Ot&#x000ed;n</surname><given-names>C.</given-names></name></person-group> (<year>2023</year>). <article-title>Mechanisms of mitochondrial microRNA regulation in cardiovascular diseases</article-title>. <source>Mech. Ageing Dev.</source>
<volume>212</volume>, <fpage>111822</fpage>. <pub-id pub-id-type="doi">10.1016/j.mad.2023.111822</pub-id>
<pub-id pub-id-type="pmid">37182718</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sum</surname><given-names>H.</given-names></name><name><surname>Brewer</surname><given-names>A. C.</given-names></name></person-group> (<year>2023</year>). <article-title>Epigenetic modifications as therapeutic targets in atherosclerosis: a focus on DNA methylation and non-coding RNAs</article-title>. <source>Front. Cardiovasc Med.</source>
<volume>10</volume>, <fpage>1183181</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2023.1183181</pub-id>
<pub-id pub-id-type="pmid">37304954</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>LncRNA Snhg8 attenuates microglial inflammation response and blood-brain barrier damage in ischemic stroke through regulating miR-425-5p mediated SIRT1/NF-&#x003ba;B signaling</article-title>. <source>J. Biochem. Mol. Toxicol.</source>
<volume>35</volume> (<issue>5</issue>), <fpage>e22724</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.22724</pub-id>
<pub-id pub-id-type="pmid">33491845</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tokarski</surname><given-names>M.</given-names></name><name><surname>Cierzniak</surname><given-names>A.</given-names></name><name><surname>Baczynska</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>Role of hypoxia on microRNA-dependant regulation of HGFA - HGF - c-Met signalling pathway in human progenitor and mature endothelial cells</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>152</volume>, <fpage>106310</fpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2022.106310</pub-id>
<pub-id pub-id-type="pmid">36182093</pub-id>
</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Urbizu</surname><given-names>A.</given-names></name><name><surname>Arnaldo</surname><given-names>L.</given-names></name><name><surname>Beyer</surname><given-names>K.</given-names></name></person-group> (<year>2023</year>). <article-title>Obtaining miRNA from saliva-comparison of sampling and purification methods</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>24</volume> (<issue>3</issue>), <fpage>2386</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24032386</pub-id>
<pub-id pub-id-type="pmid">36768706</pub-id>
</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandenwijngaert</surname><given-names>S.</given-names></name><name><surname>Ledsky</surname><given-names>C. D.</given-names></name><name><surname>Agha</surname><given-names>O.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Bagchi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>MicroRNA-425 and microRNA-155 cooperatively regulate atrial natriuretic peptide expression and cGMP production</article-title>. <source>PLoS One</source>
<volume>13</volume> (<issue>4</issue>), <fpage>e0196697</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0196697</pub-id>
<pub-id pub-id-type="pmid">29698509</pub-id>
</mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Programmable DNA nanoswitch-regulated plasmonic CRISPR/Cas12a-Gold nanostars reporter platform for nucleic acid and non-nucleic acid biomarker analysis assisted by a spatial confinement effect</article-title>. <source>Nano Lett.</source>
<volume>25</volume> (<issue>4</issue>), <fpage>1666</fpage>&#x02013;<lpage>1672</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.4c05829</pub-id>
<pub-id pub-id-type="pmid">39812375</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Circulating exosomal miRNA as diagnostic biomarkers of neurodegenerative diseases</article-title>. <source>Front. Mol. Neurosci.</source>
<volume>13</volume>, <fpage>53</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.00053</pub-id>
<pub-id pub-id-type="pmid">32351363</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>An</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Integrated analysis of the lncRNA-miRNA-mRNA network based on competing endogenous RNA in atrial fibrillation</article-title>. <source>Front. Cardiovasc Med.</source>
<volume>10</volume>, <fpage>1099124</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2023.1099124</pub-id>
<pub-id pub-id-type="pmid">37180786</pub-id>
</mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>F.</given-names></name><name><surname>Ren</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>miR-425-5p is negatively associated with atrial fibrosis and promotes atrial remodeling by targeting CREB1 in atrial fibrillation</article-title>. <source>J. Cardiol.</source>
<volume>79</volume> (<issue>2</issue>), <fpage>202</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2021.09.012</pub-id>
<pub-id pub-id-type="pmid">34688515</pub-id>
</mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN</article-title>. <source>Transl. Cancer Res.</source>
<volume>10</volume> (<issue>11</issue>), <fpage>4905</fpage>&#x02013;<lpage>4913</lpage>. <pub-id pub-id-type="doi">10.21037/tcr-21-2394</pub-id>
<pub-id pub-id-type="pmid">35116342</pub-id>
</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>miR-425-5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN</article-title>. <source>Oncol. Rep.</source>
<volume>42</volume> (<issue>6</issue>), <fpage>2550</fpage>&#x02013;<lpage>2560</lpage>. <pub-id pub-id-type="doi">10.3892/or.2019.7371</pub-id>
<pub-id pub-id-type="pmid">31638259</pub-id>
</mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y. F.</given-names></name><name><surname>Gong</surname><given-names>F. M.</given-names></name><name><surname>Wang</surname><given-names>B. S.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>MiR-425-5p promotes tumor progression via modulation of CYLD in gastric cancer</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>21</volume> (<issue>9</issue>), <fpage>2130</fpage>&#x02013;<lpage>2136</lpage>.<pub-id pub-id-type="pmid">28537672</pub-id>
</mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/&#x003b2;-catenin signaling pathway</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>111</volume>, <fpage>42</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2019.04.004</pub-id>
<pub-id pub-id-type="pmid">30986552</pub-id>
</mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>MicroRNA-425 facilitates pathogenic Th17 cell differentiation by targeting forkhead box O1 (Foxo1) and is associated with inflammatory bowel disease</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>496</volume> (<issue>2</issue>), <fpage>352</fpage>&#x02013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.01.055</pub-id>
<pub-id pub-id-type="pmid">29331376</pub-id>
</mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yi</surname><given-names>D. Y.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Human breast Milk composition and function in human health: from nutritional components to microbiome and MicroRNAs</article-title>. <source>Nutrients</source>
<volume>13</volume> (<issue>9</issue>), <fpage>3094</fpage>. <pub-id pub-id-type="doi">10.3390/nu13093094</pub-id>
<pub-id pub-id-type="pmid">34578971</pub-id>
</mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Ramakrishnan</surname><given-names>S. S.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Iwata</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Identification of microRNAs and gene regulatory networks in cleft lip common in humans and mice</article-title>. <source>Hum. Mol. Genet.</source>
<volume>30</volume> (<issue>19</issue>), <fpage>1881</fpage>&#x02013;<lpage>1893</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddab151</pub-id>
<pub-id pub-id-type="pmid">34104955</pub-id>
</mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zapata-Mart&#x000ed;nez</surname><given-names>L.</given-names></name><name><surname>&#x000c1;guila</surname><given-names>S.</given-names></name><name><surname>de Los Reyes-Garc&#x000ed;a</surname><given-names>A. M.</given-names></name><name><surname>Carrillo-Tornel</surname><given-names>S.</given-names></name><name><surname>Lozano</surname><given-names>M. L.</given-names></name><name><surname>Gonz&#x000e1;lez-Conejero</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Inflammatory microRNAs in cardiovascular pathology: another brick in the wall</article-title>. <source>Front. Immunol.</source>
<volume>14</volume>, <fpage>1196104</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1196104</pub-id>
<pub-id pub-id-type="pmid">37275892</pub-id>
</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson's disease model by targeting the miR-425-5p/TRAF5/NF-&#x003ba;B axis</article-title>. <source>J. Biochem. Mol. Toxicol.</source>
<volume>35</volume> (<issue>10</issue>), <fpage>e22867</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.22867</pub-id>
<pub-id pub-id-type="pmid">34369042</pub-id>
</mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Kuang</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Circ_0007099 upregulates GNG7 to function as a tumor inhibitor in gastric carcinoma by interacting with miR-425-3p</article-title>. <source>J. Gastrointest. Oncol.</source>
<volume>13</volume> (<issue>4</issue>), <fpage>1626</fpage>&#x02013;<lpage>1639</lpage>. <pub-id pub-id-type="doi">10.21037/jgo-22-684</pub-id>
<pub-id pub-id-type="pmid">36092318</pub-id>
</mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>LncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p</article-title>. <source>J. Ovarian Res.</source>
<volume>14</volume> (<issue>1</issue>), <fpage>109</fpage>. <pub-id pub-id-type="doi">10.1186/s13048-021-00857-2</pub-id>
<pub-id pub-id-type="pmid">34454554</pub-id>
</mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>D.</given-names></name><name><surname>Huo</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Piao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The role of exosomes and exosomal MicroRNA in cardiovascular disease</article-title>. <source>Front. Cell Dev. Biol.</source>
<volume>8</volume>, <fpage>616161</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.616161</pub-id>
<pub-id pub-id-type="pmid">33511124</pub-id>
</mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhidan</surname><given-names>X.</given-names></name><name><surname>Kedi</surname><given-names>X.</given-names></name><name><surname>Dan</surname><given-names>X.</given-names></name><name><surname>Xing</surname><given-names>S.</given-names></name><name><surname>Rui</surname><given-names>S.</given-names></name></person-group> (<year>2024</year>). <article-title>Predictive and carcinogenic roles of necroptosis-related miR-425-5p and miR-16-5p in esophageal squamous cell carcinoma</article-title>. <source>Ann. Clin. Lab. Sci.</source>
<volume>54</volume> (<issue>1</issue>), <fpage>76</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">38514064</pub-id>
</mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024b</year>). <article-title>Fibroblast-derived miR-425-5p alleviates cardiac remodelling in heart failure via inhibiting the TGF-&#x003b2;1/Smad signalling</article-title>. <source>J. Cell Mol. Med.</source>
<volume>28</volume> (<issue>21</issue>), <fpage>e70199</fpage>. <pub-id pub-id-type="doi">10.1111/jcmm.70199</pub-id>
<pub-id pub-id-type="pmid">39527465</pub-id>
</mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S. S.</given-names></name><name><surname>Jin</surname><given-names>J. P.</given-names></name><name><surname>Wang</surname><given-names>J. Q.</given-names></name><name><surname>Zhang</surname><given-names>Z. G.</given-names></name><name><surname>Freedman</surname><given-names>J. H.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges</article-title>. <source>Acta Pharmacol. Sin.</source>
<volume>39</volume> (<issue>7</issue>), <fpage>1073</fpage>&#x02013;<lpage>1084</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2018.30</pub-id>
<pub-id pub-id-type="pmid">29877320</pub-id>
</mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Mei</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024a</year>). <article-title>The MEF2A/SNHG16/miR-425-5p/NOTCH2 axis induces gemcitabine resistance by inhibiting ferroptosis in the starving bladder tumor microenvironment</article-title>. <source>Cell Signal</source>
<volume>122</volume>, <fpage>111337</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2024.111337</pub-id>
<pub-id pub-id-type="pmid">39121977</pub-id>
</mixed-citation></ref></ref-list></back></article>